




# The Patent Office



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP9 1RH



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Dated 16 February 1999



23 JAN 1998

RECEIVED BY HAND

The  
Patent  
Office

1/77

## Request for grant of a patent

(See the notes on the back of this form. You can also  
get an explanatory leaflet from the Patent Office to  
help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

P1823GB

26JAN98 E333138-1 000019  
P01/7700 25.00 - 9801499.62. Patent application number  
(The Patent Office will fill in this part)

23 JAN 1998

9801499.6

3. Full name, address and postcode of the or of  
each applicant (underline all surnames)CEREBRUS LIMITED  
Oakdene Court  
613 Reading Road, Winnersh  
Wokingham  
UNITED KINGDOM  
RG41 5UA

Patents ADP number (if you know it)

If the applicant is a corporate body, give the  
country/state of its incorporation

0703515102

4. Title of the invention

CHEMICAL COMPOUNDS - III

5. Name of your agent (if you have one)

Carpmaels &amp; Ransford

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)43 Bloomsbury Square  
London  
WC1A 2RA

Patents ADP number (if you know it)

83001

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (if you know it) the or  
each application number

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier application

Number of earlier application

Date of filing  
(day / month / year)8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an  
applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	32
Claim(s)	3
Abstract	0
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*Carpmaels & Ransford.* 23rd January 1998

12. Name and daytime telephone number of person to contact in the United Kingdom
- |                      |               |
|----------------------|---------------|
| Dr. P.N. Howard      | 0171 242 8692 |
| Carpmaels & Ransford |               |

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## CHEMICAL COMPOUNDS - III

The present invention relates to chemical compounds useful in the treatment of disorders of the central nervous system (CNS), such as anxiety and all forms of epilepsy, particularly in humans. The invention also relates to the use of such compounds, pharmaceutical preparations containing such compounds and to methods of preparing such compounds.

Anxiety disorders affect an estimated 73 million people world-wide. The benzodiazepines have provided the dominant therapy for anxiety over the past three decades and there is no doubt that they are remarkably effective anxiolytics. However, chronic administration of benzodiazepines produces severe dependence liability, withdrawal syndromes, and side effects (sedation, amnesia, muscle relaxation). The only non-benzodiazepine anxiolytic that has been launched over the past decade is the 5-HT receptor ligand buspirone (Buspar®). This drug has had a remarkable commercial success despite being regarded as a weak anxiolytic (compared with the benzodiazepines) and having a long latency to onset of therapeutic action (2-4 weeks). In addition, buspirone and all related 5-HT<sub>1A</sub> partial agonists suffer from a dose-limiting side-effect profile comprising nausea, vertigo and endocrine changes.

The aetiology of anxiety disorders is not fully understood, but it is now established that benzodiazepines act by potentiating GABAergic neurotransmission although there is strong evidence that other neurotransmitter systems are modulated indirectly - in particular, the serotonergic and noradrenergic systems. Many pharmaceutical companies have invested considerable resource into the development of serotonergic anxiolytics. However, it is now apparent that ligands selective for 5-HT receptor subtypes, despite displaying anxiolytic-like activity in a restricted range of anxiety models, have, at best, very weak and/or non-

dose-related anxiolytic effects in the clinic. The 5-HT<sub>3</sub> receptor antagonists are now discredited as psychotropics: they have a restricted range of activity in functional and anxiety models; they show no convincing anxiolytic effects in the clinic; and they are now accepted only as useful anti-emetics. The 5-HT<sub>2A</sub> antagonists similarly are regarded as ineffective in terms of psychotropic activity. The clinical utility of 5-HT<sub>1A</sub> receptor agonists and partial agonists is severely limited by their intrinsically weak action and by the dose-limiting side-effects (vertigo, endocrine changes, nausea) which become more intense as the agonist efficacy of these molecules is increased. The selective CCK<sub>B</sub> receptor antagonists have displayed an unimpressive preclinical profile similar to that of selective 5-HT ligands such as the 5-HT<sub>3</sub> antagonists.

Serotonergic anxiolytics include the selective serotonin reuptake inhibitors (SSRI's) which, in addition to displaying antidepressant properties, are also effective in anxiety disorders such as panic disorder and obsessive-compulsive disorder. However, as with their antidepressant action, the major drawback with these compounds is the long delay (6-8 weeks) in the onset of clinical improvement following chronic administration.

A strategy in recent years towards improving the clinical profile of classical benzodiazepines is that of developing benzodiazepine receptor partial agonists, according to the rationale that they would have a more selective anxiolytic action and be less liable to induce dependence. However, this approach appears to have failed owing to the very weak anxiolytic actions of these compounds and their poor side-effect profiles (there is either a low or non-existent ratio between anxiolytic and sedative doses).


US-4956359 and EP-A-0194112 disclose 3-aryloxy and 3-arylthio azetidinecarboxamides and their anti-convulsant and anti-epileptic activity. These compounds, like the

benzodiazepines, have low water solubility which leads to difficulties in formulation. The presence of an oxygen or sulphur atom, present as a linking atom between the aryl group and the azetidine ring, is a key feature of these 5 compounds since such atoms can undergo hydrogen-bonding interactions with other molecules, affect molecular conformation and increase electron density in the aryl rings.

10 There remains therefore a need for novel anxiolytic and anti-epileptic agents which do not suffer the above-mentioned drawbacks.

It has now been found that the oxygen and sulphur linking 15 atoms are not necessary for pharmacological action. It is unexpected that compounds in which such atoms are absent exhibit pharmacological activity.

According to the present invention there is provided a 20 chemical compound of formula (1)



(1)

wherein:

R<sup>1</sup> is aryl; and

25 R<sup>2</sup> is alkyl;

and pharmaceutically acceptable addition compounds thereof.

Reference in the present specification to an "alkyl" group means a branched or unbranched, cyclic or acyclic, 30 saturated or unsaturated (e.g. alkenyl (including allyl) or alkynyl (including propargyl)) hydrocarbyl radical. Where cyclic or acyclic the alkyl group is preferably C<sub>1</sub> to C<sub>12</sub>, more preferably C<sub>1</sub> to C<sub>8</sub> (such as methyl, ethyl, propyl,

isopropyl butyl, isobutyl, tert-butyl, amyl, isoamyl, hexyl, heptyl, octyl).

Reference in the present specification to an "aryl" group means a mono or bicyclic aromatic group, such as phenyl or naphthyl.

The alkyl and aryl groups may be substituted or unsubstituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 or 2 substituents. Substituents may include:

- carbon containing groups such as
- alkyl
  - aryl, arylalkyl (e.g. substituted and unsubstituted phenyl, substituted and unsubstituted benzyl);
- halogen atoms and halogen containing groups such as
- haloalkyl (e.g. trifluoromethyl);
- oxygen containing groups such as
- 20 alcohols (e.g. hydroxy, hydroxyalkyl, (aryl)(hydroxy)alkyl),
  - ethers (e.g. alkoxy, alkoxyalkyl, aryloxyalkyl),
  - aldehydes (e.g. carboxaldehyde),
  - 25 ketones (e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl, arylalkylcarbonyl, arylcarbonylalkyl),
  - acids (e.g. carboxy, carboxyalkyl),
  - 30 acid derivatives such as esters (e.g. alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl)
  - 35 and amides (e.g. aminocarbonyl, mono- or



dialkylaminocarbonyl,  
 aminocarbonylalkyl, mono- or  
 dialkylaminocarbonylalkyl,  
 arylaminocarbonyl);

5 nitrogen containing groups such as

amines (e.g. amino, mono- or  
 dialkylamino, aminoalkyl, mono-  
 or dialkylaminoalkyl),

azides,

10 nitriles (e.g. cyano, cyanoalkyl),  
 nitro;

sulphur containing groups such as

thiols, thioethers, sulphoxides and sulphones

(e.g. alkylthio, alkylsulfinyl,  
 15 alkylsufonyl, alkylthioalkyl,  
 alkylsulfinylalkyl,  
 alkylsulfonylalkyl, arylthio,  
 arylsulfinyl, arylsulfonyl,  
 arylthioalkyl, arylsulfinylalkyl,  
 20 arylsulfonylalkyl); and

heterocyclic groups containing one or more, preferably one,  
 heteroatom,

(e.g. thienyl, furanyl, pyrrolyl,  
 25 imidazolyl, pyrazolyl, thiazolyl,  
 isothiazolyl, oxazolyl,  
 pyrrolidinyl, pyrrolinyl,  
 imidazolidinyl, imidazolinyl,  
 pyrazolidinyl, tetrahydrofuranyl,  
 pyranyl, pyronyl, pyridyl,  
 30 pyrazinyl, pyridazinyl,  
 piperidyl, piperazinyl,  
 morpholinyl, thionaphthyl,  
 benzofuranyl, isobenzofuryl,  
 indolyl, oxyindolyl, isoindolyl,

indazolyl, indolyl, 7-  
 azaindolyl, isoindazolyl,  
 benzopyranyl, coumarinyl,  
 isocoumarinyl, quinolyl,  
 5 isoquinolyl, naphthridinyl,  
 cinnolinyl, quinazolinyl,  
 pyridopyridyl, benzoxazinyl,  
 quinoxadinyl, chromenyl,  
 10 chromanyl, isochromanyl and  
 carbolinyl).

Preferred substituents include alkyl, aryl, halo, or an halogen-containing group such as trifluoromethyl.

As used herein, the term "alkoxy" means alkyl-O- and  
 15 "alkoyl" means alkyl-CO-.

As used herein, the term "halogen" means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine or chlorine radical.

20 The compounds of formula (1) may exist in a number of diastereomeric and/or enantiomeric forms. Reference in the present specification to "a compound of formula (1)" is a reference to all stereoisomeric forms of the compound and includes a reference to the unseparated stereoisomers in a  
 25 mixture, racemic or non-racemic, and to each stereoisomer in its pure form.

In the compounds of formula (1), preferably  $R^1$  is substituted or unsubstituted phenyl or naphthyl, more  
 30 preferably  $R^1$  is a substituted phenyl or naphthyl, more preferably  $R^1$  is phenyl or naphthyl having 1 to 3 substituents and most preferably  $R^1$  is phenyl or naphthyl having 1 or 2 substituents. Where  $R^1$  is a phenyl having 1 substituent, the phenyl group is preferably para- or meta-

substituted. Where  $R^1$  is a phenyl having 2 substituents, the phenyl group is preferably meta- and para-substituted. The most preferred  $R^1$  groups are selected from 4-chlorophenyl, 4-fluorophenyl, 4-(trifluoromethyl)phenyl, 3-5 (trifluoromethyl)phenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluorophenyl and 4-chloro-3-fluorophenyl.

In the compounds of formula (1), preferably  $R^2$  is alkenyl, 10 alkynyl, hydroxyalkyl, alkoxyalkyl or unsubstituted saturated cyclic or acyclic hydrocarbyl. Most preferably,  $R^2$  is allyl, propargyl, or 2-hydroxypropyl.

Particularly preferred compounds are as follows:-

Chirality	R <sup>1</sup>	R <sup>2</sup>
-	4-Cl-C <sub>6</sub> H <sub>4</sub>	Allyl
-	4-F-C <sub>6</sub> H <sub>4</sub>	Allyl
-	4-F-C <sub>6</sub> H <sub>4</sub>	Propargyl
R	4-F-C <sub>6</sub> H <sub>4</sub>	MeCH(OH)CH <sub>2</sub>
-	4-Cl-C <sub>6</sub> H <sub>4</sub>	Propargyl
R	4-Cl-C <sub>6</sub> H <sub>4</sub>	MeCH(OH)CH <sub>2</sub>
S	4-F-C <sub>6</sub> H <sub>4</sub>	MeCH(OH)CH <sub>2</sub>
S	4-CF <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	MeCH(OH)CH <sub>2</sub>
-	3-CF <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	Propargyl
-	4-CF <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	Propargyl
R	4-CF <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	MeCH(OH)CH <sub>2</sub>

5

Of these, the preferred compounds are: 3-(4-Chlorophenyl)-*N*-(2-propynyl)azetidine-1-carboxamide, (S)-3-(4-Fluorophenyl)-*N*-(2-hydroxypropyl)azetidine-1-carboxamide, 3-(4-Fluorophenyl)-*N*-(2-propynyl)azetidine-1-carboxamide, 10 (R)-3-(4-Fluorophenyl)-*N*-(2-hydroxypropyl)azetidine-1-carboxamide, 3-(4-Chlorophenyl)-*N*-(2-propenyl)azetidine-1-carboxamide, (S)-3-(4-(Trifluoromethyl)phenyl)-*N*-(2-hydroxypropyl)azetidine-1-carboxamide and 3-(3-

(Trifluoromethyl)phenyl)-N-(2-propynyl)azetidine-1-carboxamide.

According to a further aspect of the present invention there is provided a compound according to the present invention for use in a method of treatment. The compounds of the present invention may be used in a method of treatment (including prophylaxis) of anxiety or epilepsy. Anxiety includes generalised anxiety disorder (GAD), panic disorder, panic disorder plus agoraphobia, simple (specific) phobias (e.g. arachnophobia, performance anxiety such as public speaking), social phobias, post-traumatic stress disorder, anxiety associated with depression, and obsessive compulsive disorder (OCD). Epilepsy is a chronic disorder characterised by recurrent seizures. Two forms of epilepsy exist - partial and generalised epilepsy - and each type is subdivided into idiopathic (cause unknown) or symptomatic (cause known). There are two fundamental types of seizures: partial seizures which includes simple partial seizures, complex partial seizures, and partial seizures secondarily generalised; and generalised seizures which includes generalised tonic-clonic seizures (grand mal), absence seizures (petit mal), myoclonic seizures, atonic seizures, clonic seizures, and tonic seizures.


According to a further aspect of the present invention there is provided use of a compound of the present invention in the manufacture of a medicament for the treatment (including prophylaxis) of anxiety or epilepsy.

The invention further provides a method of treating anxiety or epilepsy comprising administering to a patient in need of such treatment an effective dose of a compound according to the present invention.

According to a further aspect of the present invention there is provided a method of preparing a compound of the present invention.

5 Compounds of the present invention may be prepared according to the reaction scheme (where P is a nitrogen protecting group).  $R^1$  and  $R^2$  are as previously defined. The 3-aryl-3-azetidinol (III) may be formed by treatment of the ketone (II) with an organometallic reagent such as an  
10 aryllithium or an arylmagnesium halide. Removal of the hydroxyl group to give the 3-arylazetidine (IV) may be effected by several methods including, for example, catalytic hydrogenolysis; treatment with lithium or sodium and ammonia; conversion to the xanthate by treatment with  
15 carbon disulphide, methyl iodide and base, followed by tin-mediated reduction; and conversion to the 3-aryl-3-chloroazetidine analogue using an alkylsulfonyl chloride and a base, followed by a reductive dechlorination using sodium, lithium or nickel. Formation of the azetidine (V)  
20 is achieved by reaction of (IV) with a suitable nitrogen deprotection agent. For example, if P is a diphenylmethyl group, then deprotection may be carried out by either catalytic transfer hydrogenation (e.g. ammonium formate and palladium catalyst) or by treatment with 1-chloroethyl  
25 chloroformate followed by methanol. The urea (I) is formed by reaction of azetidine (V) with an N-alkylisocyanate or an N-alkylcarbamoyl chloride and a base such as triethylamine or potassium carbonate. Alternatively, the urea may be prepared directly from the azetidine (IV)  
30 without isolation of an intermediate such as the secondary amine (V). For example, when P is a diphenylmethyl group, azetidine (IV) may be treated with phosgene followed by alkylamine  $R^2NH_2$  to give urea (I) directly.

## Reaction Scheme



5The invention further provides a pharmaceutical composition comprising a compound according to the present invention in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining a compound according to the present  
 10invention with a pharmaceutically acceptable carrier or excipient.

Compounds of the present invention may be administered in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use including transmucosal and transdermal use, for example a cream, ointment, gel, aqueous or oil solution or suspension, salve, patch or plaster; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oil solution or suspension. In general the above compositions may be prepared in a conventional manner using conventional excipients, using standard techniques well known to those skilled in the art of pharmacy. Preferably, the compound is administered orally.

For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.

Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate



or glyceryl distearate, to delay absorption in the gastrointestinal tract.

Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

10 For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and  
15 isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions  
20 include ethyl and n-propyl p-hydroxybenzoate.

It will be appreciated that the dosage levels used may vary over quite a wide range depending upon the compound used, the severity of the symptoms exhibited by the patient and  
25 the patient's body weight.

The invention will now be described in detail with reference to the following examples. It will be appreciated that the invention is described by way of  
30 example only and modification of detail may be made without departing from the scope of the invention.

## EXPERIMENTAL

### Antagonism of 3-MPA-Induced Seizures

5

Several animal seizure models are available for the screening and characterisation of anticonvulsant (antiepileptic) drugs. Most models employ a chemical convulsant to induce seizures and the anticonvulsant 10 potencies of novel compounds are measured in terms of their ability to increase the dose of convulsant required to induce a seizure response (or to prolong the latency to seizure onset following a bolus dose of the convulsant). Most chemical convulsants work by blocking the 15 neurotransmitter function of gamma-aminobutyric acid (GABA), the predominant inhibitory neurotransmitter in the mammalian brain. This can be achieved by blocking the postsynaptic action of GABA using pentylenetetrazol or bicuculline, or via a presynaptic action using a GABA 20 synthesis inhibitor to decrease GABA release into the synapse. In this case, the inhibitor of glutamate decarboxylase (GAD), 3-mercaptopropionic acid (3-MPA), was used as the convulsant challenge agent. Anticonvulsant effects of test compounds were determined by their 25 abilities to significantly increase the dose of 3-MPA required to initiate a seizure response.

Male albino T/O strain mice (obtained from Tuck) weighing 28-40 g were used in these studies. Animals were assigned 30 randomly to treatment groups and vehicle or test drug (at a dose of 30mg/kg) were administered p.o. to groups of 12 animals 60 min before the administration of a bolus dose of 3-MPA intravenously. Immediately following 3-MPA administration, each mouse was placed individually into a 35 cage for observation. The seizure response of each animal

was scored quantally as present or absent (response or non-response) during the 5 min period immediately following 3-MPA administration. A seizure response was defined as the onset of the initial clonic phase of the seizure (abrupt loss of righting reflex accompanied by vocalisation). The seizure threshold (in terms of mg/kg i.v. of 3-MPA required to evoke a seizure response) was determined in each treatment group by a sequential up/down method followed by modified probit analysis of the quantal data. A range of 10 doses of 3-MPA was prepared (12.5 - 200.0 mg/kg i.v.) increasing by a constant geometric factor ( $^3\sqrt{2}$ ), which was found in pilot studies to generate suitable data for analysis by this method.

15 In these studies, 3-MPA was obtained from Sigma.

Test compounds were prepared as solutions dissolved in 45% w/v aqueous 2-hydroxypropyl- $\beta$ -cyclodextrin in distilled water. 3-MPA was dissolved in isotonic saline and its pH adjusted to 6 using 1M sodium hydroxide solution. Drugs 20 were administered in a dose volume of 10 ml/kg body weight.

### Antagonism of 3-MPA-Induced Seizures: Results of Testing

Compound	SC	SV
Example 1	42.7	15.7
Example 2	24.2	18.6
Example 3	21.4	18.6
Example 4	27.3	18.6
Example 5	32.4	15.7
Example 6	59.5	20.6
Example 7	54.4	20
Example 8	100	15.7
Example 9	29.7	14.9
Example 10	95.8	15.6
Example 15	58.4	14.1
Example 19	>200.0 <sup>a</sup>	17.2

SC = Seizure threshold after treatment with test drug

SV = Seizure threshold in vehicle-treated group

<sup>a</sup> = No seizures were observed at the top dose of 200mg/Kg i.v. of 3-MPA

**Measurement of anxiolytic activity in mice using the elevated zero-maze model.**

The elevated "zero-maze" is a modification of the elevated plus-maze model of anxiety which incorporates both traditional and novel ethological measures in the analysis of drug effects (Shepherd, J.K., Grewal, S.S., Fletcher, A., Bill, D.J. and Dourish, C.T.,. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. *Psychopharmacology*, 1994, 116, 56-64).

20

Male Sprague-Dawley rats (Charles River) weighing 300-450

gm are used. Animals are group-housed (5 per cage; cage size: 40 x 40 x 20 cm) in a temperature-controlled environment ( $20 \pm 2^\circ\text{C}$ ), under a 12h light-dark cycle (lights on: 08:00 hours). Food and water are made freely available. Four hours prior to testing, animals are transferred to clean cages and moved to the testing room in order to habituate to the testing environment.

The maze is comprised of a black Perspex annular platform (105cm diameter, 10cm width) elevated to 65cm above ground level, divided equally into four quadrants. Two opposite quadrants are enclosed by clear red Perspex walls (27cm high) on both the inner and outer edges of the platform, while the remaining two opposite quadrants are surrounded only by a Perspex "lip" (1cm high) which serves as a tactile guide to animals on these open areas. To facilitate the measurement of locomotor activity, the apparatus is divided into octants by splitting each quadrant into equal halves using high contrast white lines. The apparatus is illuminated by dim red lighting arranged in such a manner as to provide similar lux levels in both the open and closed quadrants (40-60 lux). A video camera, connected to a VCR in an adjacent observation room, is mounted overhead in order to record behaviour on the maze for subsequent analysis.

Chlordiazepoxide hydrochloride [CDP; Sigma Chemical Co. Ltd., Poole], which has previously been shown to display robust anxiolytic-like effects in the zero-maze, serves as positive control. Drugs are typically dissolved in a 45% solution of 2-hydroxy-propyl- $\beta$ -cyclodextrin, and administered orally by gavage 1 hour prior to zero-maze testing.

Rats are placed on a closed quadrant and a 5 min test

period is recorded on video-tape. The maze is cleaned with a 5% methanol/water solution and dried thoroughly between test sessions. Five behavioural parameters are scored: [1] percentage of time spent on the open areas; [2] frequency of head dips over the edge of the platform when subjects are located in either the open or the end of the closed quadrants; [3] frequency of stretch-attend postures (SAP) from closed to open quadrants, determined when the subject, on a closed quadrant, exhibits an elongated body posture stretched forward with at least the snout passing over the open/close divide; [4] frequency of rearing; and [5] the number of line crossings. Animals are scored as being in the open area when all four paws were in an open quadrant, and in the closed area only when all four paws passed over the open/closed divide. All testing is carried out between 1100 and 1700 hours.

An increase in the frequency of head dips is considered to be a measure of anxiolytic activity. The compound of example 6 was found to be effective at a dose of 100 mg/Kg.

## CHEMISTRY

### 251-(Diphenylmethyl)-3-azetidinol

(2)

The compound (2) was prepared according to the method of Anderson and Lok (*J. Org. Chem.* **1972**, *37*, 3953, the disclosure of which is incorporated herein by reference), m.p. 111-112 °C (lit. m.p. 113 °C).

### 1-Diphenylmethyl-3-azetidinone (3)

Dimethyl sulfoxide (0.36 mL, 5 mmol) was added dropwise to a stirred solution of oxalyl chloride (0.40 mL, 4.6 mmol)

in dichloromethane (20 mL) at  $-78^{\circ}\text{C}$  under an argon atmosphere. The mixture was stirred for 10 minutes then a solution of 1-(diphenylmethyl)-3-azetidinol (1.0 g, 4.2 mmol) in dichloromethane (20 mL) was added dropwise. The mixture was warmed to  $-50^{\circ}\text{C}$  and stirred for 30 minutes. Triethylamine (2.9 mL, 21 mmol) was added and the mixture warmed to room temperature. After 1 hour, water (50 mL) was added and the mixture extracted with dichloromethane (4 x 50 mL). The combined organic extracts were washed 10 (brine), dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated *in vacuo* to give 1-diphenylmethyl-3-azetidinone (3) as a pale yellow crystalline solid (1.0 g, 99 %) (lit. (S.S. Chatterjee and A. Shueb, *Synthesis*, 1973,153) m.p.  $82^{\circ}\text{C}$ ).

#### 153-(4-Chlorophenyl)-1-(diphenylmethyl)-3-azetidinol (4)

To a stirred solution of 4-chlorophenylmagnesium bromide (9.1 mL, 1.0M in diethyl ether) in diethyl ether (80 mL) at  $-78^{\circ}\text{C}$  under an argon atmosphere was added compound 3 (1.8 g, 7.6 mmol) in diethyl ether (50 mL) dropwise over 20 minutes. The reaction mixture was stirred at  $-78^{\circ}\text{C}$  for 2 hours, then slowly warmed to room temperature with stirring over 18 hours. The reaction mixture was then partitioned between aqueous ammonium acetate solution (50 mL) and 25 diethyl ether (50 mL). The aqueous layer was extracted with diethyl ether (3 x 50 mL) and the combined organic extracts were washed (water, brine), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated *in vacuo* to give the crude product as a pale yellow viscous oil in quantitative yield. A sample purified 30 for analysis by column chromatography on silica gel using 15-30% ethyl acetate-hexane as eluent and subsequent crystallisation from hexane gave 3-(4-chlorophenyl)-1-(diphenylmethyl)-3-azetidinol (4), m.p.  $108^{\circ}\text{C}$ . Found: C, 75.42; H, 5.79; N, 3.98.  $\text{C}_{22}\text{H}_{20}\text{ClNO}$  requires C, 75.53; H, 5.76; N, 4.00%.

**O-(3-(3-(4-Chlorophenyl)-1-diphenylmethyl))azetidiny1)-S-methyldithiocarbonate (5)**

To a stirred suspension of sodium hydride (0.4 g of a 60% suspension in mineral oil, 10.4 mmol) (prewashed with hexane) in THF (80 mL) was added dropwise a solution of compound 4 (1.7 g, 4.9 mmol) in THF (80 mL). The mixture was stirred for 3 hours then carbon disulphide (17.6 mL, 0.29 mol) and methyl iodide (6.1 mL, 0.1 mol) were added dropwise. The mixture was stirred at room temperature for 15 hours and then heated to 50 °C while the solvent was removed in a stream of argon. When the volume of the mixture was reduced by half, the mixture was concentrated *in vacuo* to an approximate volume of 20 mL and then partitioned between water and diethyl ether. The organic layer was washed with water and then brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated *in vacuo*. The crude product was crystallised from hexane to give O-(3-(3-(4-chlorophenyl)-1-diphenylmethyl))azetidiny1)-S-methyldithiocarbonate (5) (2.06g, 96%).

**3-(4-Chlorophenyl)-1-(diphenylmethyl)azetidine (6)**

To a stirred solution of tributyltin hydride (1.8 mL, 6.9 mmol) in dry toluene (40 mL) at reflux under an argon atmosphere was added dropwise, over 1 hour, a solution of compound 5 (2.0 g, 4.6 mmol) in toluene (40 mL). The mixture was heated under reflux for a further 2 hours then was concentrated *in vacuo*. The residue obtained was purified by flash column chromatography on silica gel using hexane and then 10% ethyl acetate-hexane as eluent. The product was recrystallised twice from hexane to give 3-(4-chlorophenyl)-1-(diphenylmethyl)azetidine (6) (0.4 g, 34%) m.p. 82 °C. Found: C, 78.94; H, 6.06; N, 4.14. C<sub>22</sub>H<sub>20</sub>ClN requires C, 79.15; H, 6.04; N, 4.20%.



**3-(4-Chlorophenyl)azetidine (7)**

To a solution of compound 6 (0.36 g, 1.1 mmol) in 1,2-dichloroethane (10 mL) containing proton sponge (0.02 g), cooled in an ice-water bath under an argon atmosphere, was added dropwise 1-chloroethyl chloroformate (0.3 mL, 3.1 mmol). The resultant solution was boiled at reflux for 4 hours, cooled and was concentrated *in vacuo*. The residue obtained was mixed with methanol (10 mL) and heated under reflux for 2 hours, then cooled and concentrated *in vacuo* to give the hydrochloride salt of 3-(4-chlorophenyl)azetidine (7) which was used without further purification.

**Example 1. 3-(4-Chlorophenyl)-N-(2-propenyl)azetidine-1-carboxamide (8)**

To the hydrochloride salt of 3-(4-chlorophenyl)azetidine (7) (approximately 1.1 mmol) in ethanol (10 mL) stirred at 0°C was added sequentially and dropwise allyl isocyanate (0.15 mL, 1.7 mmol) followed by triethylamine (0.3 mL, 2.2 mmol). After 20 minutes the reaction mixture was partitioned between aqueous ammonium chloride and ether. The organic layer was washed (water and then brine), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated *in vacuo* to give a crude product. The product obtained was purified by column chromatography on silica gel using 20% ethyl acetate-hexane as eluent to give 3-(4-chlorophenyl)-N-(2-propenyl)azetidine-1-carboxamide (8) which was recrystallised from cyclohexane/toluene (0.16 g, 61%), m.p. 112 °C. Found: C, 62.20; H, 6.23; N, 11.40. C<sub>13</sub>H<sub>15</sub>ClN<sub>2</sub>O requires C, 62.28; H, 6.03; N, 11.17%.

30

**3-(4-tert-Butylphenyl)-1-diphenylmethyl-3-azetidinol (9)**

To a stirred solution of 4-tert-butylphenylmagnesium

bromide (11.5 mL, 2.0M (Et<sub>2</sub>O)) in toluene (50 mL) at -78°C under argon, was added, dropwise, a solution of 1-diphenylmethyl-3-azetidinone (3) (5.0 g) in toluene (100 mL) over 30 minutes. The mixture was stirred for 4 hours at -78°C then warmed to room temperature and partitioned between aqueous ammonium chloride solution (50 mL) and diethyl ether (3 x 50 mL). The combined organic fractions were washed (water, brine), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. Recrystallisation from cyclohexane gave 3-(4-tert-butylphenyl)-1-diphenylmethyl-3-azetidinol (9) (6.23 g), m.p. 168-169°C (cyclohexane). Found: C, 83.68; H, 7.97; N, 3.72. C<sub>26</sub>H<sub>29</sub>NO requires C, 84.06; H, 7.87; N, 3.77%.

**15 3-(4-tert-Butylphenyl)-3-chloro-1-(diphenylmethyl)azetidine (10)**

To a stirred solution of compound (9) (6.23 g) and N,N-diisopropylethylamine (3.5 mL) in dichloromethane (100 mL) at 0°C was added, dropwise, methanesulfonyl chloride (1.4 mL). The mixture was stirred at 0°C for 18 hrs, then washed (water, brine), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The crude product was recrystallised from hexane to give 3-(4-tert-butylphenyl)-3-chloro-1-(diphenylmethyl)azetidine (10) (4.73 g) m.p. 145°C (hexane). Found: C, 80.30; H, 7.05; N, 3.64. C<sub>26</sub>H<sub>28</sub>ClN requires C, 80.08; H, 7.24; N, 3.59%.

**3-(4-tert-Butylphenyl)-1-(diphenylmethyl)azetidine (11)**

To a stirred suspension of Raney Nickel (8.6 g, wet slurry) in tertiary butanol (50 mL) and toluene (50 mL) was added a solution of 3-(4-tert-butylphenyl)-3-chloro-1-

(diphenylmethyl)azetidine (10) (4.73 g) in toluene (10 mL). The mixture was heated to 80°C for 6 hours, cooled to room temperature and filtered through kieselguhr. The filtrate was concentrated in vacuo and partitioned between diethyl ether (3 x 50 mL) and aqueous potassium carbonate solution (50 mL). The combined organic extracts were washed (water, brine), dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated in vacuo and purified by flash column chromatography (10% ethyl acetate/hexane) on silica. Recrystallisation from methanol gave 3-(4-tert-butylphenyl)-1-(diphenylmethyl)azetidine (11) (3.40 g), m.p. 95°C (methanol). Found: C, 87.84; H, 8.17; N, 3.92. C<sub>26</sub>H<sub>29</sub>N requires C, 87.84; H, 8.22; N, 3.94%.

**Example 2. 3-(4-tert-Butylphenyl)-N-(2-propenyl)azetidine-1-carboxamide (12)**

To a stirred solution of 3-(4-tert-butylphenyl)-1-(diphenylmethyl)azetidine (11) (1.0 g) in dichloromethane (10 mL) at 0°C was added dropwise a solution of 20% phosphosgene in toluene (2.5 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (10 mL) and to this solution at 0°C was added, dropwise, with stirring, allylamine (0.8 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (30 mL), washed (water, brine), dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated in vacuo and purified by flash column chromatography (50% ethyl acetate-hexane) to give 3-(4-tert-butylphenyl)-N-(2-propenyl)azetidine-1-carboxamide (12) (0.21 g), m.p. 98-100°C (diisopropyl ether). Found: C, 74.95; H, 8.97; N, 10.25. C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O requires C, 74.96; H, 8.88; N, 10.28%.

**Example 3. 3-(4-tert-Butylphenyl)-N-(2-propynyl)azetidine-1-carboxamide (13)**

To a stirred solution of 3-(4-tert-butylphenyl)-1-5 (diphenylmethyl)azetidine (11) (0.5 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (0.8 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (5 mL) and to this solution at 0°C 10 was added dropwise with stirring propargylamine (0.24 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed (water, brine), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. Trituration with diethyl ether (2 mL) gave 3-(4-tert-15 butylphenyl)-N-(2-propynyl)azetidine-1-carboxamide (13) (0.14 g), m.p. 141°C (diethyl ether). Found: C, 75.40; H, 8.19; N, 10.38. C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O requires C, 75.52; H, 8.20; N, 10.36%.

**20 Example 4. (R)-3-(4-tert-Butylphenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide (14)**

To a stirred solution of 3-(4-tert-butylphenyl)-1-25 (diphenylmethyl)azetidine (11) (0.50 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (0.8 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (5 mL) and to this solution at 0°C was added dropwise with stirring (R)-1-amino-2-propanol 30 (0.25 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed (water, brine), dried (Na<sub>2</sub>SO<sub>4</sub>) concentrated in vacuo and purified by flash column chromatography (10% methanol-ethyl acetate) to give (R)-3-(4-tert-butylphenyl)-N-(2-35 hydroxypropyl)azetidine-1-carboxamide (14) (0.35 g), m.p.

96-97°C (diisopropyl ether). Found: C, 69.59; H, 8.74; N, 9.23.  $C_{17}H_{26}N_2O$  requires C, 70.31; H, 9.02; N, 9.64%.

**3-(4-Fluorophenyl)-1-diphenylmethyl-3-azetidinol (15)**

5

To a stirred solution of 4-fluorophenylmagnesium bromide (7.0 mL, 1.0M ( $Et_2O$ )) in toluene (20 mL) at -78°C under argon, was added, dropwise, a solution of 1-diphenylmethyl-3-azetidinone (3) (1.4 g) in toluene (30 mL) over 30 minutes. The mixture was stirred for 4 hours at -78°C then warmed to room temperature and partitioned between aqueous ammonium chloride solution (50 mL) and diethyl ether (3 x 20 mL). The combined organic fractions were washed (water, brine), dried ( $Na_2SO_4$ ) and concentrated in vacuo. 15 Purification by flash column chromatography (20% ethyl acetate, hexane) gave 3-(4-fluorophenyl)-1-diphenylmethyl-3-azetidinol (15) (1.82 g). To a stirred solution of the free base (1.82 g) in ether (5 mL) was added dropwise a solution of oxalic acid (0.49 g) in acetone (1 mL). The 20 mixture was stirred for 5 minutes then filtered to give the oxalate salt hemihydrate (2.23 g), m.p. 75°C (acetone). Found: C, 66.71; H, 5.34; N, 3.04.  $C_{24}H_{22}FNO_5 \cdot 0.5H_2O$  requires C, 66.67; H, 5.32; N, 3.17%.

**25 3-(4-Fluorophenyl)-3-chloro-1-(diphenylmethyl)azetidine (16)**

To a stirred solution of 3-(4-fluorophenyl)-1-diphenylmethyl-3-azetidinol (15) (4.0 g) and N,N-30 diisopropylethylamine (3.2 mL) in dichloromethane (100 mL) at 0°C was added, dropwise, methanesulfonyl chloride (1.25 mL). The mixture was stirred at 0°C for 18 hrs, then washed (water, brine) and dried ( $Na_2SO_4$ ) and concentrated in vacuo. The crude product was recrystallised from hexane

to give 3-(4-fluorophenyl)-3-chloro-1-(diphenylmethyl)azetidine (16) (2.2 g), m.p. 108-109°C (hexane). Found: C, 75.13; H, 5.46; N, 3.93.  $C_{22}H_{19}ClFN$  requires C, 75.10; H, 5.44; N, 3.98%.

### 5 3-(4-Fluorophenyl)-1-(diphenylmethyl)azetidine (17)

To a stirred suspension of Raney Nickel (2.0 g, wet slurry) in tertiary butanol (10 mL) and toluene (50 mL) was added a solution of 3-(4-fluorophenyl)-3-chloro-1-(diphenylmethyl)azetidine (16) (1.9 g) in toluene (20 mL). The mixture was heated to 80°C for 6 hours, cooled and filtered through kieselguhr. The filtrate was concentrated in vacuo and partitioned between diethyl ether (3 x 30 mL) and aqueous potassium carbonate solution (50 mL). The combined organic extracts were washed (water, brine), dried ( $Na_2SO_4$ ), and concentrated in vacuo. Recrystallisation from diisopropyl ether gave 3-(4-fluorophenyl)-1-(diphenylmethyl)azetidine (17) (1.5 g), m.p. 65-66°C (diisopropyl ether). Found: C, 83.25; H, 6.35; N, 4.41.  $C_{22}H_{20}FN$  requires C, 83.25; H, 6.35; N, 4.41%.

20

### Example 5. 3-(4-Fluorophenyl)-N-(2-propenyl)azetidine-1-carboxamide (18)

To a stirred solution of 3-(4-fluorophenyl)-N-(diphenylmethyl)azetidine (17) (0.67 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (2.5 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (5 mL) and to this solution at 0°C was added, dropwise, with stirring, allylamine (0.5 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed (water, brine), dried ( $Na_2SO_4$ ) and concentrated in vacuo.

Recrystallisation from diisopropyl ether gave 3-(4-fluorophenyl)-N-(2-propenyl)azetidine-1-carboxamide (18) (0.30g), m.p. 119-120°C (diisopropyl ether). Found: C, 66.61; H, 6.37; N, 11.74.  $C_{13}H_{15}FN_2O$  requires C, 66.65; 5H, 6.45; N, 11.95%.

**Example 6. 3-(4-Fluorophenyl)-N-(2-propynyl)azetidine-1-carboxamide (19)**

10 To a stirred solution of 3-(4-fluorophenyl)-1-(diphenylmethyl)azetidine (17) (0.38 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (1.4 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was  
15 added dichloromethane (5 mL) and to this solution at 0°C was added, dropwise, with stirring propargylamine (0.3 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed (water, brine), dried ( $Na_2SO_4$ ) and concentrated in vacuo. The  
20 crude material was purified by flash column chromatography (50% ethyl acetate hexane) and then crystallised from diisopropyl ether to give 3-(4-fluorophenyl)-N-(2-propynyl)azetidine-1-carboxamide (19) (0.14g), m.p. 141°C (diisopropyl ether). Found: C, 67.32; H, 5.65; N, 25.11.93.  $C_{13}H_{13}FN_2O$  requires C, 67.23; H, 5.64; N, 12.06%.

**Example 7. (R)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide (20)**

30

To a stirred solution of 3-(4-fluorophenyl)-1-(diphenylmethyl)azetidine (17) (0.35 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (1.2 mL). The mixture was stirred for 90  
35 minutes then concentrated in vacuo. To the concentrate was

added dichloromethane (5 mL) and to this solution at 0°C was added dropwise with stirring (R)-1-amino-2-propanol (0.2 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed 5 (water, brine), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The crude product was purified by flash column chromatography (10% methanol-ethyl acetate) to give (R)-3-(4-fluorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide (20) (0.21g), m.p. 104-105 °C (toluene/ethanol). Found: 10C, 61.93; H, 6.97; N, 10.9. C<sub>13</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>2</sub> requires C, 61.89; H, 6.79; N, 11.10%.

**Example 8. (3-(4-Chlorophenyl)-N-(2-propynyl)azetidine-1-carboxamide (21)**

15

This compound was prepared from 3-(4-chlorophenyl-1-(diphenylmethyl)azetidine (6) and propargylamine using the procedure outlined in Example 3, m.p. 160 °C (diethyl ether). Found C, 62.85; H, 5.38; N, 10.89 C<sub>13</sub>H<sub>13</sub>ClN<sub>2</sub>O requires C, 62.78; H, 5.27; N, 11.26%.

**Example 9. (R)-3-(4-Chlorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide (22)**

25 This compound was prepared from compound (6) and (R)-1-amino-2-propanol using the procedure outlined in Example 4, m.p. 92-93 °C (diethyl ether-toluene). Found: C, 58.97; H, 6.38; N, 9.96. C<sub>13</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub>.0.2PhCH<sub>3</sub>, requires C, 60.23; H, 6.48; N, 9.76%.

30

**Example 10: (S)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide (23)**

This compound was prepared from compound (17) and (S)-1-



amino-2-propanol using the procedure described for compound (20). Found: C, 61.94; H, 6.72; N, 11.1.  $C_{13}H_{17}FN_2O_2$  requires C, 61.89; H, 6.79; N, 11.10%.

**53-(3,4-Dichlorophenyl)-1-(diphenylmethyl)azetidin-3-ol (24)**

This compound was prepared from compound (3) and 3,4-dichlorophenylmagnesium bromide using the procedure described for compound (4).

10

**3-(3,4-Dichlorophenyl)-3-chloro-1-(diphenylmethyl)azetidine (25)**

This compound was prepared from compound (24) using the 15 procedure described for compound (10).

**3-(3,4-Dichlorophenyl)-1-(diphenylmethyl)azetidine (26)**

This compound was prepared from compound (25) using the procedure described from compound (11).

**20 Example 11. 3-(3,4-Dichlorophenyl)-N-(2-propynyl)azetidine carboxamide (27)**

This compound was prepared from compound (26) and propargylamine using the procedure described for compound (12).

**25 Example 12. (R)-3-(3,4-Dichlorophenyl)-N-(2-hydroxypropyl)azetidine carboxamide (28)**

This compound was prepared from compound (26) and (R)-1-amino-2-propanol using the procedure described for compound (12). Found: C, 51.58; H, 5.33; N, 9.26.  $C_{13}H_{16}Cl_2N_2O_2$  30 requires C, 51.50; H, 5.32; N, 9.24%.

**Example 13. (S)-3-(3,4-Dichlorophenyl)-N-(2-hydroxypropyl)azetidine carboxamide (29)**

This compound was prepared from compound (26) and (S)-1-amino-2-propanol using the procedure described for compound 5 (12). Found: C, 51.47; H, 5.30; N, 9.18.  $C_{13}H_{16}Cl_2N_2O_2$  requires C, 51.50; H, 5.32; N, 9.24%.

**3-(4-(Trifluoromethyl)phenyl)-1-(diphenylmethyl)azetidin-3-ol (30)**

10 This compound was prepared from compound (3) and 4-(trifluoromethyl)phenylmagnesium bromide using the procedure described for compound (4).

**3-Chloro-3-(4-(trifluoromethyl)phenyl)-1-(diphenylmethyl)azetidine (31)**

This compound was prepared from compound (30) using the procedure described for compound (10).

**3-(4-(Trifluoromethyl)phenyl)-1-(diphenylmethyl)azetidine (32)**

20 This compound was prepared from compound (31) using the procedure described for compound (11).

**Example 14. (R)-3-(4-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine carboxamide (33)**

This compound was prepared from compound (32) and (R)-1-amino-2-propanol using the procedure described for compound 5 (12). Found: C, 54.78; H, 5.75; N, 9.01.  $C_{14}H_{17}F_3N_2O_2 \cdot 0.25 H_2O$  requires C, 54.81; H, 5.71, N, 9.13%.

**Example 15. (S)-3-(4-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine carboxamide (34)**

10

This compound was prepared from compound (32) and (S)-1-amino-2-propanol using the procedure described for compound (12). Found: C, 54.75; H, 5.68; N, 9.09.  $C_{14}H_{17}F_3N_2O_2 \cdot 0.25 H_2O$  requires C, 54.81; H, 5.71; N, 9.13%.

15

**Example 16. 3-(4-(Trifluoromethyl)phenyl)-N-(2-propynyl)azetidine-1-carboxamide (35)**

This product was prepared from compound (32) and 20 propargylamine using the procedure described for compound (12).

**3-(3-(Trifluoromethyl)phenyl)-1-(diphenylmethyl)azetidin-3-ol (36)**

This compound was prepared from compound (3) and 25 (trifluoromethyl)phenylmagnesium bromide using the procedure described for compound (4).

**3-Chloro-3-(3-(trifluoromethyl)phenyl)-(diphenylmethyl)azetidine (37)**

30

This compound was prepared from compound (32) using the procedure described for compound (10).

**3-(3-(Trifluoromethyl)phenyl)-1-(diphenylmethyl)azetidine  
(38)**

5 This compound was prepared from compound (37) using the procedure described for compound (11).

**Example 17. (R)-3-(3-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine carboxamide (39)**

10

This compound was prepared from compound (38) and (R)-1-amino-2-propanol using the procedure described for compound (12).

15 **Example 18. (S)-3-(3-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine carboxamide (40)**


This compound was prepared from compound (38) and (S)-1-amino-2-propanol using the procedure described for compound  
20 (12).

**Example 19. 3-(3-(Trifluoromethyl)phenyl)-N-(2-propynyl)azetidine-1-carboxamide (41)**

25 This product was prepared from compound (38) and propargylamine using the procedure described for compound (12).

CLAIMS

1. A compound of formula (1)



5

(1)

wherein

R<sup>1</sup> is aryl; and

R<sup>2</sup> is alkyl;

and pharmaceutically acceptable addition compounds thereof.

10

2. A compound according to claim 1 wherein R<sup>1</sup> is a substituted or unsubstituted phenyl or naphthyl.
3. A compound according to claim 1 or 2 wherein R<sup>1</sup> has 1, 2 or 3 substituent groups.
4. A compound according to claim 1, 2 or 3 wherein R<sup>1</sup> is a meta- or para-substituted phenyl group.
205. A compound according to claim 1, 2, 3 or 4 wherein R<sup>1</sup> is chlorophenyl, fluorophenyl or (trifluoromethyl)phenyl.
6. A compound according to claim 1, 2 or 3 wherein R<sup>1</sup> is a meta,para-disubstituted phenyl group.
- 25
7. A compound according to claim 6 wherein R<sup>1</sup> is 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-chloro-4-fluorophenyl or 4-chloro-3-fluorophenyl.
308. A compound according to any one of claims 1 to 7 wherein R<sup>2</sup> is alkenyl, alkynyl, hydroxyalkyl or

alkoxyalkyl.

9. A compound according to any one of claims 1 to 8 wherein R<sup>2</sup> is allyl, propargyl or 2-hydroxypropyl.

5

10. A compound according to any one of claims 1 to 7 wherein R<sup>2</sup> is unsubstituted saturated cyclic or acyclic hydrocarbyl.

1011. A compound according to claim 1 wherein the compound is selected from 3-(4-Chlorophenyl)-N-(2-propynyl)azetidine-1-carboxamide, (S)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide, 3-(4-Fluorophenyl)-N-(2-propynyl)azetidine-1-carboxamide, (R)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide, 15 3-(4-Chlorophenyl)-N-(2-propenyl)azetidine-1-carboxamide, (R)-3-(4-Chlorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide, 3-(4-Fluorophenyl)-N-(2-propenyl)azetidine-1-carboxamide, 3-(4-(Trifluoromethyl)phenyl)-N-(2-propynyl)azetidine-1-carboxamide, (R)-3-(4-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide, (S)-3-(4-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide and 3-(3-(Trifluoromethyl)phenyl)-N-(2-propynyl)azetidine-1- 25 carboxamide.

12. A compound according to any one of claims 1 to 11 for use in a method of treatment.

3013. Use of a compound according to any one of claims 1 to 11 in the manufacture of a medicament for the treatment (including prophylaxis) of anxiety or epilepsy.

14. A pharmaceutical composition comprising a compound 35 according to any one of claims 1 to 11 in combination with

a pharmaceutically acceptable carrier or excipient.

15. A method of treating anxiety or epilepsy comprising administering to a patient in need of such treatment an effective dose of a compound according to any one of claims 1 to 11.

PCT/48 99/00223

22-1-99

Compma. e Ransford